On December 16, Allergan Aesthetics announced the successful completion of its acquisition of Soliton, maker of the Resonic Rapid Acoustic Pulse (RAP) device, which initially received U.S. Food and Drug Administration (FDA) 510(k) clearance for the short-term improvement in the appearance of cellulite. That clearance has now been expanded to long-term improvement up to one year.
In recent clinical data submitted to the FDA, Resonic demonstrated significant improvement in the appearance of cellulite, and 97.6% of participants (n=67) found there was good improvement in the appearance of cellulite at 52-weeks post-treatment.
"We welcome the Soliton team to Allergan Aesthetics and the opportunity to offer health care providers and their patients a new, noninvasive option to reduce the appearance of cellulite," said Carrie Strom, president, Global Allergan Aesthetics and Senior Vice President, AbbVie. "In a recent survey of aesthetic consumers, cellulite was cited as a top 5 aesthetic concern, and this technology offers a new approach to treatment."
Resonic has also received FDA 510(k) clearance for use in conjunction with laser for black ink tattoo removal in Fitzpatrick Skin Type I-III patients.
